UA98955C2 - Гетероциклические соединения и их применение - Google Patents

Гетероциклические соединения и их применение

Info

Publication number: UA98955C2
Authority: UA; Ukraine
Prior art keywords: inflammatory; disorders; myelo; restricted; diseases
Prior art date: 2007-03-23

Application number

UAA200910741A

Other languages

English (en)

Ukrainian (uk)

Inventor

И. Чень

Тимоти Д. Кашинг

Джейсон А. Дюке

Лопес де Турисо Феликс Гонзалез

Сяолинь Хао

Сяо Хе

Брайан Лукас

Лоренс Р. Макги

Андрэас Рейчелт

Роберт М. Рзаса

Дженифер Сеганиш

Йонсук Шин

Давэй Чжан

Original Assignee

Амген Инк.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-03-23

Filing date

2008-03-24

Publication date

2012-07-10

2008-03-24 Application filed by Амген Инк. filed Critical Амген Инк.

2012-07-10 Publication of UA98955C2 publication Critical patent/UA98955C2/ru

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/28—Oxygen atom
- C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurology (AREA)
Dermatology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Transplantation (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Ophthalmology & Optometry (AREA)
Oncology (AREA)
Pulmonology (AREA)
Vascular Medicine (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

UAA200910741A 2007-03-23 2008-03-24 Гетероциклические соединения и их применение UA98955C2 (ru)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US91956807P	2007-03-23	2007-03-23

Publications (1)

Publication Number	Publication Date
UA98955C2 true UA98955C2 (ru)	2012-07-10

Family

ID=39645618

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UAA200910741A UA98955C2 (ru)	2007-03-23	2008-03-24	Гетероциклические соединения и их применение

Country Status (24)

Country	Link
US (6)	US8193199B2 (ru)
EP (2)	EP3045458A1 (ru)
JP (2)	JP5527761B2 (ru)
KR (1)	KR101504773B1 (ru)
CN (1)	CN101715453B (ru)
AU (1)	AU2008231304B2 (ru)
BR (1)	BRPI0809141A2 (ru)
CA (1)	CA2681136C (ru)
CR (2)	CR11053A (ru)
DK (1)	DK2137186T3 (ru)
EA (1)	EA017389B1 (ru)
ES (1)	ES2563458T3 (ru)
HR (1)	HRP20160350T1 (ru)
HU (1)	HUE028954T2 (ru)
IL (1)	IL200867A (ru)
MX (1)	MX2009009968A (ru)
NZ (1)	NZ579834A (ru)
PL (1)	PL2137186T3 (ru)
PT (1)	PT2137186E (ru)
RS (1)	RS54706B1 (ru)
SI (1)	SI2137186T1 (ru)
UA (1)	UA98955C2 (ru)
WO (1)	WO2008118468A1 (ru)
ZA (1)	ZA201308294B (ru)

Families Citing this family (123)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1831225A2 (en)	2004-11-19	2007-09-12	The Regents of the University of California	Anti-inflammatory pyrazolopyrimidines
MX2008012928A (es)	2006-04-04	2009-03-06	Univ California	Antagonistas de pi3-cinasa.
CA2680853C (en) *	2007-03-23	2012-07-17	Amgen Inc.	3- substituted quinoline or quinoxaline derivatives and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors
UA98955C2 (ru)	2007-03-23	2012-07-10	Амген Инк.	Гетероциклические соединения и их применение
WO2009046448A1 (en)	2007-10-04	2009-04-09	Intellikine, Inc.	Chemical entities and therapeutic uses thereof
WO2009081105A2 (en)	2007-12-21	2009-07-02	Ucb Pharma S.A.	Quinoxaline and quinoline derivatives as kinase inhibitors
NZ717410A (en)	2008-01-04	2017-07-28	Intellikine Llc	Heterocyclic containing entities, compositions and methods
US8193182B2 (en)	2008-01-04	2012-06-05	Intellikine, Inc.	Substituted isoquinolin-1(2H)-ones, and methods of use thereof
JP5547099B2 (ja)	2008-03-14	2014-07-09	インテリカイン，エルエルシー	キナーゼ阻害剤および使用方法
WO2009114874A2 (en)	2008-03-14	2009-09-17	Intellikine, Inc.	Benzothiazole kinase inhibitors and methods of use
WO2009155121A2 (en)	2008-05-30	2009-12-23	Amgen Inc.	Inhibitors of pi3 kinase
US20110224223A1 (en)	2008-07-08	2011-09-15	The Regents Of The University Of California, A California Corporation	MTOR Modulators and Uses Thereof
MX2011000216A (es)	2008-07-08	2011-03-29	Intellikine Inc	Inhibidores de cinasa y metodos para su uso.
US8703778B2 (en)	2008-09-26	2014-04-22	Intellikine Llc	Heterocyclic kinase inhibitors
JP5819195B2 (ja)	2008-10-16	2015-11-18	ザリージェンツオブザユニバーシティオブカリフォルニア	融合環ヘテロアリールキナーゼ阻害剤
GB0819593D0 (en)	2008-10-24	2008-12-03	Ucb Pharma Sa	Therapeutic agents
US8476431B2 (en)	2008-11-03	2013-07-02	Itellikine LLC	Benzoxazole kinase inhibitors and methods of use
GB0821693D0 (en) *	2008-11-27	2008-12-31	Ucb Pharma Sa	Therapeutic agents
US8592415B2 (en) *	2009-02-11	2013-11-26	Reaction Biology Corp.	Selective kinase inhibitors
ES2598358T3 (es)	2009-02-13	2017-01-27	Ucb Pharma, S.A.	Derivados de quinolina como inhibidores de PI3K quinasa
EP2403847B1 (en)	2009-03-06	2016-03-02	UCB Biopharma SPRL	Triazine derivatives as kinase inhibitors
EP2426135A4 (en)	2009-04-27	2013-02-20	Shionogi & Co	UREA DERIVATIVE WITH PI3K-INHIBITING EFFECT
CA2760791C (en)	2009-05-07	2017-06-20	Intellikine, Inc.	Heterocyclic compounds and uses thereof
GB0908957D0 (en) *	2009-05-22	2009-07-01	Ucb Pharma Sa	Therapeutic agents
UY32743A (es) *	2009-06-25	2010-12-31	Amgen Inc	Compuestos heterocíclicos y sus usos
TW201602113A (zh)	2009-06-29	2016-01-16	英塞特公司	作為ｐｉ３ｋ抑制劑之嘧啶酮
TW201111385A (en) *	2009-08-27	2011-04-01	Biocryst Pharm Inc	Heterocyclic compounds as janus kinase inhibitors
WO2011047384A2 (en)	2009-10-16	2011-04-21	The Regents Of The University Of California	Methods of inhibiting ire1
ES2534096T3 (es)	2009-11-12	2015-04-17	Ucb Pharma, S.A.	Derivados de piridina y pirazina bicíclicos condensados como inhibidores de quinasa
WO2011058112A1 (en)	2009-11-12	2011-05-19	Ucb Pharma S.A.	Fused bicyclic pyrazole derivatives as kinase inhibitors
WO2011058110A1 (en)	2009-11-12	2011-05-19	Ucb Pharma S.A.	Quinoline and quinoxaline derivatives as kinase inhibitors
WO2011058111A1 (en)	2009-11-12	2011-05-19	Ucb Pharma S.A.	Aminopurine derivatives as kinase inhibitors
WO2011058109A1 (en)	2009-11-12	2011-05-19	Ucb Pharma S.A.	Fused bicyclic pyrrole and imidazole derivatives as kinase inhibitors
EP2499129B1 (en)	2009-11-12	2014-07-30	UCB Pharma, S.A.	Quinoline and quinoxaline derivatives as kinase inhibitors
US8759359B2 (en) *	2009-12-18	2014-06-24	Incyte Corporation	Substituted heteroaryl fused derivatives as PI3K inhibitors
WO2011075628A1 (en) *	2009-12-18	2011-06-23	Amgen Inc.	Heterocyclic compounds and their uses
US8680108B2 (en) *	2009-12-18	2014-03-25	Incyte Corporation	Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors
WO2011093365A1 (ja) *	2010-01-27	2011-08-04	協和発酵キリン株式会社	含窒素複素環化合物
AR081823A1 (es)	2010-04-14	2012-10-24	Incyte Corp	DERIVADOS FUSIONADOS COMO INHIBIDORES DE PI3Kd
CN103002738A (zh)	2010-05-21	2013-03-27	英特利凯恩有限责任公司	用于激酶调节的化学化合物、组合物和方法
JO2998B1 (ar)	2010-06-04	2016-09-05	Amgen Inc	مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
US9062055B2 (en)	2010-06-21	2015-06-23	Incyte Corporation	Fused pyrrole derivatives as PI3K inhibitors
JP2013533883A (ja) *	2010-06-30	2013-08-29	アムジエン・インコーポレーテツド	ＰＩ３Ｋδ阻害剤としての含窒素複素環化合物
US20130085131A1 (en) *	2010-07-01	2013-04-04	Amgen Inc.	Heterocyclic compounds and their uses
US8759371B2 (en) *	2010-07-01	2014-06-24	Amgen Inc.	Heterocyclic compounds and their uses
WO2012003271A1 (en)	2010-07-02	2012-01-05	Amgen Inc.	Heterocyclic compounds and their use as inhibitors of pi3k activity
AR082799A1 (es) *	2010-09-08	2013-01-09	Ucb Pharma Sa	Derivados de quinolina y quinoxalina como inhibidores de quinasa
ES2693257T3 (es) *	2010-09-14	2018-12-10	Exelixis, Inc.	Inhibidores de PI3K-delta y métodos para su uso y fabricación
US20140031355A1 (en) *	2010-11-04	2014-01-30	Amgen Inc.	Heterocyclic compounds and their uses
AU2011326427B2 (en)	2010-11-10	2016-01-07	Infinity Pharmaceuticals Inc.	Heterocyclic compounds and uses thereof
MX2013005567A (es) *	2010-11-17	2013-10-30	Amgen Inc	Derivados de quinolina como inhibidores de pik3.
EP3660016A1 (en)	2010-12-20	2020-06-03	Incyte Holdings Corporation	N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
AR084824A1 (es)	2011-01-10	2013-06-26	Intellikine Inc	Procesos para preparar isoquinolinonas y formas solidas de isoquinolinonas
WO2012148540A1 (en)	2011-02-23	2012-11-01	Intellikine, Llc	Combination of kanase inhibitors and uses threof
WO2012125629A1 (en)	2011-03-14	2012-09-20	Incyte Corporation	Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
WO2012135009A1 (en)	2011-03-25	2012-10-04	Incyte Corporation	Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
AR088218A1 (es)	2011-07-19	2014-05-21	Infinity Pharmaceuticals Inc	Compuestos heterociclicos utiles como inhibidores de pi3k
US8969363B2 (en)	2011-07-19	2015-03-03	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
EP2751093A1 (en)	2011-08-29	2014-07-09	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
JP6342805B2 (ja)	2011-09-02	2018-06-13	ザリージェンツオブザユニバーシティオブカリフォルニア	置換ピラゾロ［３，４−ｄ］ピリミジンおよびその用途
TWI648277B (zh)	2011-09-02	2019-01-21	美商英塞特控股公司	作為ｐｉ３ｋ抑制劑之雜環基胺
MX352672B (es)	2011-09-27	2017-12-04	Amgen Inc	Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer.
WO2013052699A2 (en) *	2011-10-04	2013-04-11	Gilead Calistoga Llc	Novel quinoxaline inhibitors of pi3k
PT2790705T (pt)	2011-12-15	2018-01-24	Novartis Ag	Utilização de inibidores da atividade ou função de pi3k
US20150011569A1 (en) *	2011-12-15	2015-01-08	Philadelphia Health & Education Corporation D/B/A Drexel University College Of Medicine	NOVEL P13K p110 INHIBITORS AND METHODS OF USE THEREOF
AR090548A1 (es)	2012-04-02	2014-11-19	Incyte Corp	Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
US8940742B2 (en)	2012-04-10	2015-01-27	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
US8828998B2 (en)	2012-06-25	2014-09-09	Infinity Pharmaceuticals, Inc.	Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
WO2014052669A1 (en)	2012-09-26	2014-04-03	The Regents Of The University Of California	Modulation of ire1
AR095192A1 (es) *	2013-01-31	2015-09-30	Vertex Pharma	Quinolina y quinazolinamidas como modulares de canales de sodio
AU2014219075C1 (en)	2013-02-19	2018-09-06	Amgen Inc.	Cis-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
WO2014151863A1 (en)	2013-03-14	2014-09-25	Amgen Inc.	Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer
US9481667B2 (en)	2013-03-15	2016-11-01	Infinity Pharmaceuticals, Inc.	Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
JOP20200296A1 (ar)	2013-06-10	2017-06-16	Amgen Inc	عمليات صنع وأشكال بلورية من mdm2 مثبط
US9751888B2 (en)	2013-10-04	2017-09-05	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
SG10201902074UA (en)	2013-10-04	2019-04-29	Infinity Pharmaceuticals Inc	Heterocyclic compounds and uses thereof
KR102305351B1 (ko)	2013-11-11	2021-09-24	암젠 인크	암의 치료를 위한, mdm2 억제제 및 하나 이상의 추가적 약제학적 활성 제제를 포함하는 조합 요법
US10328080B2 (en)	2013-12-05	2019-06-25	Acerta Pharma, B.V.	Therapeutic combination of PI3K inhibitor and a BTK inhibitor
SG11201607705XA (en)	2014-03-19	2016-10-28	Infinity Pharmaceuticals Inc	Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
US20150320755A1 (en)	2014-04-16	2015-11-12	Infinity Pharmaceuticals, Inc.	Combination therapies
WO2015171725A1 (en)	2014-05-06	2015-11-12	Amgen Inc.	Hydrate, crystalline hydrate and crystalline anhydrate forms of n-((1s)-1-(7-fluoro-2-(2-pyridinyl)-3-quinolinyl)ethyl)-9h-purin-6-amine, pharmaceutical compositions containing them and methods for treating cancer.
CN104086551B (zh) *	2014-06-06	2016-09-21	人福医药集团股份公司	化合物及其制备方法和用途
WO2015191677A1 (en)	2014-06-11	2015-12-17	Incyte Corporation	Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
EP3164400A1 (en)	2014-07-04	2017-05-10	Lupin Limited	Quinolizinone derivatives as pi3k inhibitors
EP2974729A1 (en)	2014-07-17	2016-01-20	Abivax	Quinoline derivatives for use in the treatment of inflammatory diseases
US20170224819A1 (en)	2014-08-11	2017-08-10	Acerta Pharma B.V.	Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a CDK 4/6 Inhibitor
RS62713B1 (sr)	2014-08-11	2022-01-31	Acerta Pharma Bv	Terapeutske kombinacije btk inhibitora i bcl-2 inhibitora
HRP20220738T1 (hr)	2014-08-11	2022-08-19	Acerta Pharma B.V.	Terapijske kombinacije inhibitora btk, inhibitora pd-1 i/ili inhibitora pd-l1
WO2016054491A1 (en)	2014-10-03	2016-04-07	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
CA2964113A1 (en) *	2014-10-14	2016-04-21	La Jolla Institute Of Allergy & Immunology	Inhibitors of low molecular weight protein tyrosine phosphatase and uses thereof
BR112017015019A2 (pt)	2015-01-16	2018-01-30	The General Hospital Corporation	compostos para melhorar a splicing de mrna
US9637488B2 (en)	2015-01-29	2017-05-02	Fuqiang Ruan	Heterocyclic compounds as inhibitors of class I PI3KS
HUE060953T2 (hu)	2015-02-27	2023-04-28	Incyte Holdings Corp	Eljárások PI3K inhibitor elõállítására
CN106008479B (zh)	2015-03-06	2020-01-10	南京圣和药业股份有限公司	作为磷脂酰肌醇3-激酶δ抑制剂的取代嘧啶类化合物及其应用
GB201506786D0 (en) *	2015-04-21	2015-06-03	Ucb Biopharma Sprl	Therapeutic use
US9988401B2 (en)	2015-05-11	2018-06-05	Incyte Corporation	Crystalline forms of a PI3K inhibitor
WO2016183060A1 (en)	2015-05-11	2016-11-17	Incyte Corporation	Process for the synthesis of a phosphoinositide 3-kinase inhibitor
CA2998469A1 (en)	2015-09-14	2017-03-23	Infinity Pharmaceuticals, Inc.	Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
US10045981B2 (en)	2015-11-24	2018-08-14	Jakpharm, Llc	Selective kinase inhibitors
US10792283B2 (en) *	2016-03-05	2020-10-06	Hangzhou Zhengxiang Pharmaceuticals Co., Ltd.	Quinoline analogs as phosphatidylinositol 3-kinase inhibitors
US10759806B2 (en)	2016-03-17	2020-09-01	Infinity Pharmaceuticals, Inc.	Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
WO2017214269A1 (en)	2016-06-08	2017-12-14	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
US11147818B2 (en)	2016-06-24	2021-10-19	Infinity Pharmaceuticals, Inc.	Combination therapies
TW201813963A (zh)	2016-09-23	2018-04-16	美商基利科學股份有限公司	磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh)	2016-09-23	2018-05-01	美商基利科學股份有限公司	磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh)	2016-09-23	2018-07-16	美商基利科學股份有限公司	磷脂醯肌醇3-激酶抑制劑
CN108069899B (zh) *	2016-11-18	2021-01-08	中国科学院大连化学物理研究所	一种制备2,3-取代喹啉类衍生物的方法
US11066420B2 (en)	2017-05-01	2021-07-20	Sanford Burnham Prebys Medical Discovery Institute	Inhibitors of low molecular weight protein tyrosine phosphatase (LMPTP) and uses thereof
JOP20190272A1 (ar)	2017-05-22	2019-11-21	Amgen Inc	مثبطات kras g12c وطرق لاستخدامها
CA3075046A1 (en)	2017-09-08	2019-03-14	Amgen Inc.	Inhibitors of kras g12c and methods of using the same
US10442799B1 (en)	2018-04-07	2019-10-15	Fuqiang Ruan	Heterocyclic compounds and uses thereof
MA52501A (fr)	2018-05-04	2021-03-10	Amgen Inc	Inhibiteurs de kras g12c et leurs procédés d'utilisation
MX2020012261A (es)	2018-06-12	2021-03-31	Amgen Inc	Inhibidores de kras g12c que comprenden un anillo de piperazina y uso de estos en el tratamiento del cancer.
JP7377679B2 (ja)	2018-11-19	2023-11-10	アムジエン・インコーポレーテツド	がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
EP3669873A1 (en)	2018-12-20	2020-06-24	Abivax	Quinoline derivatives for use ine the traeatment of inflammation diseases
EP3738593A1 (en)	2019-05-14	2020-11-18	Amgen, Inc	Dosing of kras inhibitor for treatment of cancers
SG11202112855WA (en)	2019-05-21	2021-12-30	Amgen Inc	Solid state forms
CN112574176B (zh) *	2019-09-27	2024-03-15	隆泰申医药科技(南京)有限公司	一种杂芳基类化合物及其应用
WO2021076655A1 (en)	2019-10-15	2021-04-22	Amgen Inc.	Combination therapy of kras inhibitor and shp2 inhibitor for treatment of cancers
US20230028414A1 (en)	2019-12-16	2023-01-26	Amgen Inc.	Dosing regimen of kras g12c inhibitor
CN114276326B (zh) *	2021-03-09	2022-11-11	南京征祥医药有限公司	喹啉化合物的盐及制备方法和应用
CN113218936B (zh) *	2021-06-07	2021-09-10	江苏欣诺科催化剂有限公司	锇酸钾的纯度检测方法
EP4380930A1 (en) *	2021-08-11	2024-06-12	Taizhou Eoc Pharma Co., Ltd.	A cyclin-dependent kinase inhibitor

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT72878B (en)	1980-04-24	1983-03-29	Merck & Co Inc	Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
US6043062A (en)	1995-02-17	2000-03-28	The Regents Of The University Of California	Constitutively active phosphatidylinositol 3-kinase and uses thereof
GB9611460D0 (en)	1996-06-01	1996-08-07	Ludwig Inst Cancer Res	Novel lipid kinase
US5858753A (en)	1996-11-25	1999-01-12	Icos Corporation	Lipid kinase
US5822910A (en)	1997-10-02	1998-10-20	Shewmake; I. W.	Fishing line tensioning device
CA2400447C (en) *	2000-02-17	2008-04-22	Amgen Inc.	Kinase inhibitors
US20050165029A1 (en) *	2004-01-13	2005-07-28	Ambit Biosciences Corporation	Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
AU2005249380C1 (en) *	2004-04-23	2012-09-20	Exelixis, Inc.	Kinase modulators and methods of use
WO2006114180A1 (de)	2005-04-25	2006-11-02	Merck Patent Gmbh	Neuartige aza-heterozyklen als kinase-inhibitoren
US20090170848A1 (en)	2006-03-02	2009-07-02	Smithkline Beecham Corporation	Thiazolones for use as pi3 kinase inhibitors
EP1996191A4 (en)	2006-03-02	2010-05-19	Glaxosmithkline Llc	THIAZOLONE AS A PI3 KINASE INHIBITOR
US20080221161A1 (en)	2007-02-09	2008-09-11	Kalypsys, Inc.	Heterocyclic modulators of tgr5 for treatment of disease
UA98955C2 (ru) *	2007-03-23	2012-07-10	Амген Инк.	Гетероциклические соединения и их применение
MX2010003449A (es)	2007-09-26	2010-04-27	Astellas Pharma Inc	Derivado de quinolona.
WO2009081105A2 (en) *	2007-12-21	2009-07-02	Ucb Pharma S.A.	Quinoxaline and quinoline derivatives as kinase inhibitors
US8703778B2 (en) *	2008-09-26	2014-04-22	Intellikine Llc	Heterocyclic kinase inhibitors
GB0819593D0 (en) *	2008-10-24	2008-12-03	Ucb Pharma Sa	Therapeutic agents
GB0821693D0 (en) *	2008-11-27	2008-12-31	Ucb Pharma Sa	Therapeutic agents
ES2598358T3 (es)	2009-02-13	2017-01-27	Ucb Pharma, S.A.	Derivados de quinolina como inhibidores de PI3K quinasa
CA2760791C (en) *	2009-05-07	2017-06-20	Intellikine, Inc.	Heterocyclic compounds and uses thereof
UY32743A (es) *	2009-06-25	2010-12-31	Amgen Inc	Compuestos heterocíclicos y sus usos
ES2534096T3 (es)	2009-11-12	2015-04-17	Ucb Pharma, S.A.	Derivados de piridina y pirazina bicíclicos condensados como inhibidores de quinasa
WO2011075628A1 (en)	2009-12-18	2011-06-23	Amgen Inc.	Heterocyclic compounds and their uses

2008
- 2008-03-24 UA UAA200910741A patent/UA98955C2/ru unknown
- 2008-03-24 WO PCT/US2008/003962 patent/WO2008118468A1/en active Application Filing
- 2008-03-24 ES ES08727163.1T patent/ES2563458T3/es active Active
- 2008-03-24 EP EP16152820.3A patent/EP3045458A1/en not_active Withdrawn
- 2008-03-24 EA EA200901276A patent/EA017389B1/ru not_active IP Right Cessation
- 2008-03-24 MX MX2009009968A patent/MX2009009968A/es active IP Right Grant
- 2008-03-24 KR KR1020097022066A patent/KR101504773B1/ko active IP Right Grant
- 2008-03-24 HU HUE08727163A patent/HUE028954T2/en unknown
- 2008-03-24 PL PL08727163.1T patent/PL2137186T3/pl unknown
- 2008-03-24 CA CA2681136A patent/CA2681136C/en active Active
- 2008-03-24 AU AU2008231304A patent/AU2008231304B2/en active Active
- 2008-03-24 JP JP2009554600A patent/JP5527761B2/ja active Active
- 2008-03-24 EP EP08727163.1A patent/EP2137186B1/en active Active
- 2008-03-24 RS RS20160208A patent/RS54706B1/en unknown
- 2008-03-24 SI SI200831591T patent/SI2137186T1/sl unknown
- 2008-03-24 NZ NZ579834A patent/NZ579834A/en unknown
- 2008-03-24 DK DK08727163.1T patent/DK2137186T3/en active
- 2008-03-24 BR BRPI0809141-2A patent/BRPI0809141A2/pt not_active Application Discontinuation
- 2008-03-24 CN CN2008800170109A patent/CN101715453B/zh active Active
- 2008-03-24 US US12/079,406 patent/US8193199B2/en active Active
- 2008-03-24 PT PT87271631T patent/PT2137186E/pt unknown
2009
- 2009-09-10 IL IL200867A patent/IL200867A/en active IP Right Grant
- 2009-10-05 CR CR11053A patent/CR11053A/es unknown
2010
- 2010-07-21 CR CR11582A patent/CR11582A/es unknown
2012
- 2012-05-10 US US13/468,212 patent/US8586739B2/en active Active
- 2012-05-10 US US13/468,234 patent/US8901135B2/en active Active
2013
- 2013-10-22 JP JP2013218925A patent/JP5819382B2/ja active Active
- 2013-11-05 ZA ZA2013/08294A patent/ZA201308294B/en unknown
2014
- 2014-10-22 US US14/520,899 patent/US9873701B2/en active Active
2016
- 2016-04-06 HR HRP20160350TT patent/HRP20160350T1/hr unknown
2017
- 2017-12-13 US US15/841,153 patent/US20180105532A1/en not_active Abandoned
2019
- 2019-10-17 US US16/656,328 patent/US20200048265A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20200048265A1 (en)	2020-02-13
US8193199B2 (en)	2012-06-05
KR101504773B1 (ko)	2015-03-20
CA2681136C (en)	2012-05-22
AU2008231304B2 (en)	2011-05-12
WO2008118468A1 (en)	2008-10-02
JP5527761B2 (ja)	2014-06-25
BRPI0809141A2 (pt)	2014-08-26
CR11053A (es)	2009-10-23
PL2137186T3 (pl)	2016-09-30
JP2014058526A (ja)	2014-04-03
EA200901276A1 (ru)	2010-04-30
US8901135B2 (en)	2014-12-02
JP2010522179A (ja)	2010-07-01
JP5819382B2 (ja)	2015-11-24
EP2137186B1 (en)	2016-01-27
RS54706B1 (en)	2016-08-31
US9873701B2 (en)	2018-01-23
NZ579834A (en)	2012-03-30
HUE028954T2 (en)	2017-01-30
EP2137186A1 (en)	2009-12-30
CA2681136A1 (en)	2008-10-02
DK2137186T3 (en)	2016-04-18
US20150045361A1 (en)	2015-02-12
US20180105532A1 (en)	2018-04-19
EA017389B1 (ru)	2012-12-28
CR11582A (es)	2011-01-10
US20120220585A1 (en)	2012-08-30
US8586739B2 (en)	2013-11-19
IL200867A (en)	2014-11-30
US20090137581A1 (en)	2009-05-28
AU2008231304A1 (en)	2008-10-02
CN101715453B (zh)	2012-06-27
HRP20160350T1 (hr)	2016-05-06
IL200867A0 (en)	2010-05-17
MX2009009968A (es)	2009-10-08
US20120220586A1 (en)	2012-08-30
EP3045458A1 (en)	2016-07-20
KR20100015795A (ko)	2010-02-12
CN101715453A (zh)	2010-05-26
SI2137186T1 (sl)	2016-04-29
ES2563458T3 (es)	2016-03-15
ZA201308294B (en)	2014-07-30
PT2137186E (pt)	2016-03-30

Publication	Publication Date	Title
UA98955C2 (ru)	2012-07-10	Гетероциклические соединения и их применение
MX2011013666A (es)	2012-03-06	Compuestos heterociclicos y sus usos.
TN2012000449A1 (en)	2014-01-30	Heterocyclic compounds and their uses
MX2013007261A (es)	2013-11-04	Compuestos heterociclicos y sus usos.
MX2009009913A (es)	2009-10-16	Derivados de quinolina o benzopirazina y sus usos para el tratamiento de enfermedades inflamatorias, enfermedades autoinmunitarias o varias clases de canceres.
MX2011013667A (es)	2012-03-06	Compuestos heterociclicos y sus usos.
MX2012015135A (es)	2013-05-06	Compuestos heterociclicos y su uso como inhibidores de la actividad pi3k.
MX2011013510A (es)	2012-03-07	Compuestos heterociclicos y sus usos.
MX2012015134A (es)	2013-05-06	Compuestos heterociclicos y su uso como inhibidores de actividad de pi3k.
MX2011013901A (es)	2012-05-08	Derivados de 4h-pirido [1,2-a] pirimidin-4-ona como inhibidores de pi3k.
MX2012015143A (es)	2013-07-03	Compuestos heterociclicos que contienen nitrogeno como inhibidores de pi3k delta.
MX2009010050A (es)	2009-10-12	Derivados de quinolina o quinoxalina 3-sustituidos y su uso como inhibidores de fosfotidilinositol 3-cinasa (p13k).
MX2012015147A (es)	2013-05-01	Compuestos heterociclicos y su uso como inhibidores de la actividad pi3k.
PH12014502246A1 (en)	2014-12-15	Heterocyclic compounds and their uses
PH12018502336A1 (en)	2019-07-29	Benzazepine derivative, preparation method , pharmaceutical composition and use thereof
PH12020551390A1 (en)	2021-11-22	AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS
MX2018011046A (es)	2019-05-06	Composiciones y metodos para tratar canceres.
CY1117196T1 (el)	2017-04-05	Ετεροκυκλικες ενωσεις και χρησεις αυτων
AR090705A1 (es)	2014-12-03	Compuestos de piridina y pirimidina y sus usos como inhibidores de fosfatidilinositol 3-quinasa (pi3k)
CY1114775T1 (el)	2016-12-14	Παραγωγα 3-υποκατεστημενης κινολινης ή κινοξαλινης και η χρηση τους ως αναστολεων της 3-κινασης φωσφατιδυλινοσιτολης (ρι3κ)
MX2017007648A (es)	2017-10-11	Composicion farmaceutica que comprende compuesto biciclico de amida heterociclica aromatica que contiene nitrogeno como ingrediente activo.
UY34748A (es)	2014-10-31	Compuestos heterocíclicos y sus usos